KR950005311A - 티에노피리미딘 유도체, 그의 제조방법 및 용도 - Google Patents

티에노피리미딘 유도체, 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR950005311A
KR950005311A KR1019940021232A KR19940021232A KR950005311A KR 950005311 A KR950005311 A KR 950005311A KR 1019940021232 A KR1019940021232 A KR 1019940021232A KR 19940021232 A KR19940021232 A KR 19940021232A KR 950005311 A KR950005311 A KR 950005311A
Authority
KR
South Korea
Prior art keywords
hydrogen
group
compound
optionally substituted
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019940021232A
Other languages
English (en)
Korean (ko)
Inventor
슈이찌 후루야
노부오 쪼
데쓰야 오따끼
도시후미 와따나베
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR950005311A publication Critical patent/KR950005311A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019940021232A 1993-08-26 1994-08-26 티에노피리미딘 유도체, 그의 제조방법 및 용도 Ceased KR950005311A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP21197293 1993-08-26
JP93-211972 1993-08-26
JP14812694 1994-06-29
JP94-148126 1994-06-29

Publications (1)

Publication Number Publication Date
KR950005311A true KR950005311A (ko) 1995-03-20

Family

ID=26478451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940021232A Ceased KR950005311A (ko) 1993-08-26 1994-08-26 티에노피리미딘 유도체, 그의 제조방법 및 용도

Country Status (11)

Country Link
EP (1) EP0640606B1 (enExample)
KR (1) KR950005311A (enExample)
CN (1) CN1106663A (enExample)
AT (1) ATE208393T1 (enExample)
CA (1) CA2130859A1 (enExample)
DE (1) DE69428952T2 (enExample)
FI (2) FI943912A7 (enExample)
HU (1) HU218939B (enExample)
NO (1) NO307565B1 (enExample)
RU (1) RU2142275C1 (enExample)
TW (1) TW276256B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US6048863A (en) 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
UY23948A1 (es) * 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd Derivados de anillos condensados de tiofeno su producción y uso.
EP0846119B1 (en) * 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
EP0781774B1 (en) * 1995-12-08 2002-07-31 Takeda Chemical Industries, Ltd. Prolactin production inhibitory agents
US5828149A (en) * 1996-07-18 1998-10-27 Baker Hughes Incorported Lubricant inducer pump for electrical motor
US6413724B1 (en) 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
WO1998018781A2 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
US6025371A (en) * 1996-10-28 2000-02-15 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6469014B1 (en) 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
PT1107973E (pt) * 1998-08-28 2004-03-31 Astrazeneca Ab Novas tieno¬2,3-d| pirimidinodionas processo para a sua preparacao e sua utilizacao em terapia
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
AU2001252825A1 (en) * 2000-05-04 2001-11-12 Astrazeneca Ab Thieno(2,3-d)pyrimidinediones and their use as pharmaceuticals
EP1322651B1 (en) * 2000-09-22 2008-01-23 N.V. Organon Bicyclic heteroaromatic compounds
RU2225866C1 (ru) * 2002-11-18 2004-03-20 Халиуллин Азат Наилевич Калиевая соль 2-[5(6)-нитро-1-(тиетанил-3)-бензимидазолил-2-тио]уксусной кислоты, проявляющая кардиотоническую активность
EP3628320B1 (en) * 2011-11-11 2022-03-16 Gilead Apollo, LLC Acc inhibitors and uses thereof
CN102920695B (zh) * 2012-11-16 2014-08-06 蔡进 苯并呋喃类内皮素受体拮抗剂及用途
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016081649A1 (en) * 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
CA3005900C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Triazole acc inhibitors and uses thereof
MX2018006286A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc pirazolicos y usos de los mismos.
CN108699078A (zh) 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
CN121202886A (zh) * 2024-06-26 2025-12-26 浙江养生堂天然药物研究所有限公司 杂环类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02225485A (ja) * 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
US5082838A (en) * 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
TW270116B (enExample) * 1991-04-25 1996-02-11 Hoffmann La Roche

Also Published As

Publication number Publication date
HUT71116A (en) 1995-11-28
CN1106663A (zh) 1995-08-16
FI943912L (fi) 1995-06-05
RU94030480A (ru) 1996-10-10
FI943912A0 (fi) 1994-08-25
NO943146D0 (no) 1994-08-25
EP0640606A1 (en) 1995-03-01
ATE208393T1 (de) 2001-11-15
NO307565B1 (no) 2000-04-25
TW276256B (enExample) 1996-05-21
RU2142275C1 (ru) 1999-12-10
EP0640606B1 (en) 2001-11-07
DE69428952D1 (de) 2001-12-13
FI990387A0 (fi) 1999-02-23
DE69428952T2 (de) 2002-06-27
CA2130859A1 (en) 1995-02-27
HU218939B (hu) 2001-01-29
HU9402453D0 (en) 1994-10-28
FI943912A7 (fi) 1995-06-05
FI990387A7 (fi) 1999-02-23
NO943146L (no) 1995-02-27

Similar Documents

Publication Publication Date Title
KR950005311A (ko) 티에노피리미딘 유도체, 그의 제조방법 및 용도
EP1345920B1 (en) Novel sulfamides and their use as endothelin receptor antagonists
US6812344B1 (en) 1-(4-Arylpiperazin-1-yl)-ω-[N-(α,ω-dicarboximidoL)]-alkanes useful as uro-selective α1-adrenoceptor blockers
Atwal et al. Dihydropyrimidine calcium channel blockers 51: bicyclic dihydropyrimidines as potent mimics of dihydropyridines
JP2000503005A (ja) ピロロピリミジンおよびその製造法
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
HK1046688A1 (zh) 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
EP0539086A3 (en) Condensed pyrimidine derivatives and their use as angiotensine ii antagonists
DE60206756D1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
CZ288030B6 (cs) Sulfonamidové sloučeniny a farmaceutické přípravky na jejich bázi
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
MX2010008269A (es) Inhibidores de hsp90.
KR20010083874A (ko) 약제용 퀴나졸린 유도체
AU8345491A (en) Heterocyclic derivatives
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
WO2003084935A3 (en) Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
AU775194B2 (en) Bis-sulfonamides
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
ES2154644T3 (es) Derivados antidepresivos 3-halofenilpiperazinil propil de triazolonas y triazoldionas sustituidas.
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
AU6670196A (en) Thienopyrimidine derivatives, their production and use
PL198815B1 (pl) Pochodne 4-heterocyklilosulfonoamidylo-6-metoksy-5-(2-metoksyfenoksy)-2-pirydylopirymidyny, środek farmaceutyczny, zastosowanie pochodnych 4-heterocyklilosulfonoamidylo-6-metoksy-5-(2-metoksyfenoksy)-2-pirydylopirymidyny, ich wytwarzanie i związki pośrednie
WO2002062798A3 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000